SPECC1L

Across TCGA pan-cancer cohorts, SPECC1L mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SPECC1L data layer compared with 26 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SPECC1L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SPECC1L expression acts as an unfavorable survival marker.

HNSC, PDAC, and GBM are the cancer types where SPECC1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.495	0.788	.001	28	view →
PDAC	DFS	Quartile	II,III,IV	0.292	0.498	.003	15	view →
GBM	OS	Median	All	0.767	0.860	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SPECC1L–HNSC (OS)

Open the HNSC breakdown →